Overview

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and efficacy of CDP870 self-injection administered for 24 weeks or longer in subjects who are participating in the long-term treatment study (Study 275-08-002 or Study 275-08-004) of CDP870 administered concomitantly with or without Methotrexate.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

UCB Japan Co. Ltd.

Treatments:

Certolizumab Pegol